Target Price | €70.00 |
Price | €87.00 |
Deviation |
19.54%
register free of charge
|
Number of Estimates | 1 |
1 Analyst has issued a Hella price target 2026.
The average Hella target price is €70.00.
This is
19.54%
register free of charge
|
|
A rating was issued by 1 analysts: 0 Analysts recommend Hella to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Hella stock has an average upside potential 2026 of
19.54%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion € | 8.02 | 8.00 |
0.89% | 0.33% | |
EBITDA Margin | 12.36% | 12.71% |
1.97% | 2.83% | |
Net Margin | 4.40% | 3.44% |
32.44% | 21.87% |
1 Analyst has issued a sales forecast Hella 2025 . The average Hella sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Hella 2025 . The average Hella EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast Hella 2025 . The average Hella net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share € | 3.18 | 2.47 |
33.61% | 22.33% | |
P/E | 35.47 | |
EV/Sales | 1.20 |
1 Analysts have issued a Hella forecast for earnings per share. The average Hella EPS is
This results in the following potential growth metrics and future valuations:
Analyst | Rating | Action | Date |
---|---|---|---|
HSBC |
Locked
➜
Locked
|
Locked | Aug 25 2024 |
Analyst Rating | Date |
---|---|
Locked
HSBC:
Locked
➜
Locked
|
Aug 25 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.